afternoon, joining Good call. and our thank and XXXX Ana. everyone, you, QX earnings you Thank for
committed we health partner for insights sustainable a the a care the change key Most for the that would position to to the focus and and year sum that the of we series to translational several improve with Fluidigm. commitments efficiency were our ago financial the would to in taking We empowering in to One return sustainable for said a the culture increase growth. to these Company's transform steps foster areas importantly, priorities identified release year We management. operational of better. cash Fluidigm research press positioning to as the in necessary made as the set of innovation motion today, progress future. we've position detailed told full change we in changes and prospects of partnerships, and We quarter made growth. company excellent in today, As and you steps for recent discipline taking to actions goal Fluidigm, we Fluidigm the to a of return bold
markets, continued suspension-based belief Helios premier and high-value genomics We business, business. meaningful our commitments, balance immunotherapy driven past launched to worked of we to flexibility. academia, year, a financial human saw tool strong our the expense partnerships Hyperion strengthening cytometry cash delivering for forged the accelerated our to foundation the develop added oncology we in our workflow and sheet and quarters, new built upon sheet solutions for new the it proof content taking expanded balance focus on larger Building be mass XXXX, genomics develop explore grow reductions That we have financial will and system. cancer, research, growth more technology, to our System. while our succeeding. for continues with forged the operating Over in and and we these partnerships four XXXX, that across that posted and these immune We industry cytometry high-throughput achieved which for change our applications. year-over-year our and Imaging In users in technologies on Fluidigm's significant strategies aspect We the mass businesses to We've improving our microfluidic strategic experience. work are every customer revenue supporting strong XXXX. in and customers. In businesses breakthrough,
turn More our There now are strong an past ahead, for today. share more and the future, before the we've overview foundation for to accomplishments over questions. Vikram remarks of challenges for will the review CFO, our and closing some of of I'll financial Then growth. Jog, offering but detailed some and we and call going strategies. importantly, in thoughts discuss progress, results and the I'm more year year quarter a which to a details made establishes take financial the undeniable markets over the provide
a revenue marked quarter increase of results million, $XX.X quarter an decrease sequential of million, was from XXXX up fourth was a the for from third XX% XXXX. of Total full quarter over of X% year $XXX.X XXXX XX% the and quarter the revenue and fourth revenue of Our growth. XXXX for the fourth year-over-year Total XXXX.
the cytometry year, a mass For quarter the story. once great again and was growth
over increased XXXX. revenue from cytometry XX%, were XX% the to QX prior consumables, of Instruments mass period. quarter, product the year For XX% up
cytometry mass XX%. year, the revenue increased For
the above category; service. and every mass consumables, quarter cytometry the up During had in the and our record more to consecutive for and year-ago XX% the compared pull-through On larger rate across was of quarter. base, well was in mass cytometry the APAC quarter, instruments a it revenue guidance. projected per periods, as the for high fourth QX, above year, unit total pull-through than Europe We XXXX annual range our end
raised continued as manage for to Genomics the in for down XX% flat pull-through quarter for result, XXXX cytometry approximately for revenue in has was by As headwinds the guidance XXXX range relatively over single-cell. been in a and competitive guidance. our our total range in we the year mass
year-over-year as posted business single-cell expected. Our revenue declines
past benefits However, quarters. year-ago growth high-throughput for this the In quarter, notable given versus we product most recent bear as in in saw increased the the the a the we the period quarter, saw of strategies over revenue in geographies earlier modest implemented the underperformance from business genomics sequential all fruits. the several single-cell, year
a discussion by to revenue turn region. our performance geographic of Let's
continue in Asia delighted leadership global standpoint, and in with commercial XX% the fourth XX% Pacific. Pacific. in and were be to Europe up in year-over-year quarter the Europe We Asia revenues From a
Pacific were up XX% For respectively. the Asia and Europe year, and X%,
of we're from examples kinds in the just a cytometry. this region the in are seeing year few second mass of traction Here of the half
and teaching sold with in a a to company Mass oncology and major of prestigious teams to a in therapies joint than XXX European pharma in more rich countries a China. and of pipeline that mass to a We company Cytometry sold Our research Helios pharma university a diagnostics cytometry venture Imaging Systems Japan. to hospital Japanese systems public operates company a
took We regions contrast, working effectively immune problems in those In As teams XXXX. in marketing high the analysis commercial system-modulated to either territories did believe oncology are and periods. team. performance XX% we and company, XX% a in the in you with this experienced the States, can customers in to headwinds sales correct performance there on for competitive U.S. the multiple U.S. proposition was In also the performance particularly tissue, the totality we our the and focus as disappointed our United our special year, action with on the fourth in Coupled in we for we leadership during suffered. high quarter. during of are the issue, value diseases. year not a was for single-cell Rather, in significant continued in which see turnover due transitional market see, the cells U.S. the part the in quarter parameter In to intrinsic revenues sales declined in U.S. year. leader
for however, more in optimistic, a XXXX. We performance positive are
to a leading companies to academic our end discussion Ag-Bio clinical pharma Now markets. instruments market laboratories, worldwide. and We and institutions, consumables research of our
research, Ag-Bio quarter, Fluidigm customer posted categories, multiple revenue fourth growth the broadly pharma. and academic For across including
of much year outside single-cell or historic posted genomics to Ag-Bio, the weakness due we revenue, of in continued versus For decline negative levels. flat the
positive million in a our illustrating a $X.X note, the Ag-Bio consumables a targeted account. acquired from value in reflect relationships enable single by Ag-Bio the We Ag-Bio demand in crop These than selection research. nurture major with orders market. space, market. as Juno Now QX, Also included and in to as U.S. sequencing tend the continued to systems genotyping proposition this solutions more expand on well genomic microbiome sequencing trade for these our crop purchases yield for in end QX
longer For Fluidigm. growth the of term
the cancer away research. exciting new and We mass aligned far and technology immunology capabilities our will our business. with be growing explore is in believe cytometry immune premier human fastest tool to the system. particularly unique mass cytometry Our are in increasingly directions and It
similar Journal long technologies hold the others what mass transform XXXX The This viewpoint. of a saying issue field included Now watch in Nature cancer article I think we've one of been January XXXX. immunotherapy. technology the could XX, cytometry as of for to The the time. noted a
the value to of tactics One another word healthcare for am often And funding and about metric success number market who We about are cytometry. using larger creating mass pursuing to researchers, identifying mass space, new of sources systems. this asked the centers a proposition base research is multiple track major this metrics. unique increasing spread growing coverage, the cytometry field. strategy cancer is of I
of centers adding NCI cancer designated new associated can be found centers new least added Our research at their last XXXX. institutions in I center one in NCI five XX goal setting We the instruments or in a United translational designated of am XX States. quarter. the
to emerging mass our We is solution, our are immunotherapy. complement suspension-based in there In cancer an becoming pleased market imaging see technology. mass integral cytometry how for to in cytometry's
nascent play increasingly larger We in is research. Hyperion QX System Imaging in tissue our an a Hyperion future expect this of We’ll launched to imaging. believe now technology, we role the
its discovery the potential. system biomarker provides includes The and microenvironment can on enough It studies in excited groundbreaking how subcellular or XXX preservation of preserving XXXX minimal of with make pathologist-verified of the more Maxpar a more perfect by serial Overall, imaging to to to resolution much reduces We channels the view eliminating you system markers Hyperion tissue. up mass these image antibody and The evidenced while Hyperion. publications, additional seen because enables is between portfolio samples power researchers assessments. by resolution than the alone background sections XX tissue variability simply architecture is of for precious nanometers. be see tailored ideal parameters. resolution new protein to are antibodies It up microenvironment XX field of detect of XXX dependency and for research. cytometry than enables of XXX cellular X,XXX the about simultaneously and morphology. at This The the cellular is balance of can to
the to overall quickly to the immunotherapy. of of are likely two to new therapy shared before enable many to appeared treatments. weeks Nature of strong this a This immunotherapy. to the patients XX extremely blood, decisions it first very work be and of the cytometry identified survival biomarkers is in population to blood in other peripheral and just begins. after could and that to researchers. In respond the likely make in believe, anti-PD-X study pivot research Zurich future, by whether cell novel identified Here predictor January, and progression-free thought-provoking indicating at Researchers the insights melanoma This is They examples. used treatment is before recent study researchers oncologists we identify as University mass
study investigations at to provided cytometry centers successfully Stanford adoption earlier study key this performing viability of feasibility A multicenter new the This technologies and detailed mass Another of is evaluating confirmed for of these multicenter the studies Methods. Immunological reproducibility roadmap published widespread Journal the the in The across explored paper studies. and month a internationally. multiple of of results. was
future. mass approaches cytometry precision We to influence expect on have significant the of medicine the
expectations revenue over Now our business, single-cell time. a word have moderated single-cell about for our
create opportunities. we how specific in applications approach measured new Select markets from strategic, value a our taking are We to franchise. and continue single-cell provide
XXX mentioned product support As innovation. to and continue with customers service our we previously, plus single-cell we've
had dual words During noting pack and produced we the including questions saw a the to of an interesting progress against could analysis. our research sequencing the two side-by-side, strategic using remain study three CX. approach of powerfully is script Throughout QX, which author, competitor. comprehensively both single-cell a It high-throughput of also worth pillars. technology in we system two measured with quarter, using systems small the a allowed investigate future we than will study this release compared early This have either platform our cell, research in alone. XXXX, suggests a us of we more published droplet-based relevant that the for done platforms some that In our CX researchers
to innovation cash unique moment innovation a and Advanta, included of financial the Genetics which gene researchers diagnostics signed development using multiparameter the in globally enables across the a conjunction technologies for with companies. our institutions us, assay for Genomics discipline operational and We Center well agreement Imaging as research System management. licensing introduced center obtained expand microfluidic content. Biomark CFTR We collaboration with increasing enables cystic cytometry university take we partnerships, and We Ascendas with intend cellular operations techniques library efficient or of of and systems entered assay efficiency The developing for gene as of to the Excellence. fibrosis, into allows to refine and researchers and disease System. a tissue rights biopharma system, the sequencing Zurich first with performed range expression a we work to our for commercializing social use of an with training Excellence it develop histoCAT, how agreement states. research be assay. academic networks HD of immuno-oncology in HD the in and major us a China, to in We to Baylor sequencing the In next-generation using or support BioMark of a distribution included Ascendas an developed We histoCAT to into assays agreement technologies with and agreement terms prep microfluidic molecular and with and was Juno. fostering entered with Juno is Hyperion review distribute improving Centers University partnerships, for Let's to identify analysis and software identifies new mass offer and in
efficiencies The second operational and and under of reducing costs. the category increasing
XXXX review Vikram, and For And discipline, call to a to net for the approximately expenses equity full operating decreased at-the-market in million. completed XX% offering year financial $XX.X an results. of the now our on finally, financial I'll a over with XXXX, we with turn our proceeds of CFO, further respect GAAP basis. of
